FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Top Story

J&J to invest $1B into Elan, scoops up drug program

After months of rumors regarding potential deals, Ireland's Elan Pharmaceuticals announced this morning that Johnson & Johnson will invest a billion dollars into the company while taking control of Elan's rights in a key Alzheimer's drug program. Read more

Headlines

Sanofi unveils R&D makeover

As promised, Sanofi-Aventis announced today that it's overhauling its R&D operations in a bid to boost productivity. Noting its "social responsibility," the company is not planning layoffs, but says it will restructure through "voluntary staff departures." Read more

Profile

Emerging Drug Developer: Rexahn Pharmaceuticals

Over the course of its eight-year history, Rexahn Pharmaceuticals' rep was been built primarily around its successful advancement of three key drug programs covering two distinct therapeutic areas: CNS and cancer. Now Rexahn--which was founded by Chang Ahn, a scientist and former FDA official--would like to develop a reputation for signing up development partners. That's why Rockville, MD-based Rexahn recruited Chief Business Officer Rick Soni a little less than a year ago. Report